Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Liabilities and Shareholders Equity (2022 - 2025)

Prokidney (PROK) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $335.6 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 23.92% to $335.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 billion through Dec 2025, down 18.72% year-over-year, with the annual reading at $335.6 million for FY2025, 23.92% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $335.6 million at Prokidney, down from $351.6 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $532.4 million in Q3 2022, with the low at $250.8 million in Q1 2022.
  • Average Liabilities and Shareholders Equity over 4 years is $417.0 million, with a median of $430.8 million recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity soared 97.47% in 2023, then dropped 25.94% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $518.0 million in 2022, then dropped by 18.81% to $420.6 million in 2023, then grew by 4.88% to $441.1 million in 2024, then dropped by 23.92% to $335.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $335.6 million, $351.6 million, and $372.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.